Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Thiogenesis Therapeutics Corp (TTIPF)

Thiogenesis Therapeutics Corp (TTIPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Most Recent Stories

More News
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026

Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue ImprovementSan Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI)...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

San Diego, California--(Newsfile Corp. - January 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar

Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome TrialSan Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosingSan Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX:...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis

Trial achieved biological proof-of-concept, dose discovery and biomarker improvementSan Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Announces Extension to Investor Relations Agreement

San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update

San Diego, California--(Newsfile Corp. - September 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU

San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference

Dr. Rioux to Highlight Industry-Leading Clinical Programs in MELAS and Leigh Syndrome SpectrumSan Diego, California--(Newsfile Corp. - June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX:...

TTI.VN : 0.520 (+1.96%)
TTIPF : 0.4000 (unch)

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 0.4000
1st Support Level N/A
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 0.4000
Fibonacci 61.8% 0.4000
Fibonacci 50% 0.4000
Fibonacci 38.2% 0.4000
Last Price 0.4000
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar